blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3194379

EP3194379 - BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  09.10.2020
Database last updated on 25.09.2024
FormerExamination is in progress
Status updated on  07.09.2018
FormerRequest for examination was made
Status updated on  23.06.2017
FormerThe international publication has been made
Status updated on  13.03.2017
Most recent event   Tooltip09.10.2020Application deemed to be withdrawnpublished on 11.11.2020  [2020/46]
Applicant(s)For all designated states
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
[2017/30]
Inventor(s)01 / MENGEL, Anne
Kavalierstr. 15
13187 Berlin / DE
02 / LERCHEN, Hans-Georg
Sürderstr.3
51375 Leverkusen / DE
03 / MÖWES, Manfred
Maßmannstr. 9
12163 Berlin / DE
04 / MÜLLER, Thomas
Wiesenau 30-32
60323 Frankfurt / DE
05 / BÄRFACKER, Lars
Ulenberg Str. 3d
40223 Düsseldorf / DE
06 / HITCHCOCK, Marion
1471 Beacon Street
Brookline, MA 02446 / US
07 / CLEVE, Arwed
Konstanzer Str. 8
10707 Berlin / DE
08 / KUHNKE, Joachim
Schulstr. 16
14482 Potsdam / DE
09 / BRIEM, Hans
Emser Str. 3
Berlin 10719 / DE
10 / SIEMEISTER, Gerhard
Reimerswalder Steig 26
13503 Berlin / DE
11 / BONE, Wilhelm
Drewitzer Str. 46
13467 Berlin / DE
12 / FERNANDEZ-MONTALVAN, Amaury Ernesto
Kopenhagener Str. 42
10437 Berlin / DE
13 / SCHRÖDER, Jens
Chausseestrasse 50b
10115 Berlin / DE
14 / MÖNNING, Ursula
Eichendamm 5
15569 Woltersdorf / DE
15 / HOLTON, Simon
Niklasstr. 14a
14163 Berlin / DE
 [2017/30]
Representative(s)BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 50
40789 Monheim am Rhein / DE
[N/P]
Former [2017/30]BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 10
40789 Monheim am Rhein / DE
Application number, filing date15763619.217.09.2015
[2017/30]
WO2015EP71340
Priority number, dateEP2014018560419.09.2014         Original published format: EP 14185604
EP2015017690315.07.2015         Original published format: EP 15176903
[2017/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016042084
Date:24.03.2016
Language:EN
[2016/12]
Type: A1 Application with search report 
No.:EP3194379
Date:26.07.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 24.03.2016 takes the place of the publication of the European patent application.
[2017/30]
Search report(s)International search report - published on:EP24.03.2016
ClassificationIPC:C07D401/14, C07D403/14, A61K31/506, A61P35/00
[2017/30]
CPC:
A61K31/506 (EP,EA,KR,US); C07D401/14 (EP,CN,EA,KR,US); A61P35/00 (EP);
A61P35/02 (EP); A61P35/04 (EP); A61P43/00 (EP);
C07D403/14 (EP,CN,EA,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/30]
Extension statesBA19.04.2017
ME19.04.2017
Validation statesMA19.04.2017
TitleGerman:BENZYLSUBSTITUIERTE INDAZOLE ALS BUB1-INHIBITOREN[2017/30]
English:BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS[2017/30]
French:INDAZOLES À SUBSTITUANTS BENZYLE UTILISÉS COMME INHIBITEURS DE BUB1[2017/30]
Entry into regional phase19.04.2017National basic fee paid 
19.04.2017Designation fee(s) paid 
19.04.2017Examination fee paid 
Examination procedure13.03.2017Date on which the examining division has become responsible
19.04.2017Examination requested  [2017/30]
02.11.2017Amendment by applicant (claims and/or description)
11.09.2018Despatch of a communication from the examining division (Time limit: M04)
10.01.2019Reply to a communication from the examining division
26.04.2019Despatch of a communication from the examining division (Time limit: M04)
22.08.2019Reply to a communication from the examining division
02.12.2019Despatch of a communication from the examining division (Time limit: M04)
15.04.2020Application deemed to be withdrawn, date of legal effect  [2020/46]
24.06.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2020/46]
Fees paidRenewal fee
12.09.2017Renewal fee patent year 03
11.09.2018Renewal fee patent year 04
13.09.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XDI]WO2013050438  (BAYER PHARMA AG [DE], et al) [XD] 18 * compound 2-51-1; page 178; claims 1, 10-17 *[I] 1-21
by applicantUS5011472
 WO2013050438
 WO2013092512
 WO2013167698
 WO2014147203
 WO2014147204
 WO2014202590
 WO2014202588
 WO2014202584
 WO2014202583
 WO2015063003
    - HANAHAN D; WEINBERG RA, CELL, (2000), vol. 100, page 57
    - HANAHAN D; WEINBERG RA, CELL, (2011), vol. 144, page 646
    - SUIJKERBUIJK SJ; KOPS GJ, BIOCHEM. BIOPHYS. ACTA, (2008), vol. 1786, page 24
    - MUSACCHIO A; SALMON ED, NAT. REV. MOL. CELL. BIOL., (2007), vol. 8, page 379
    - BOLANOS-GARCIA VM; BLUNDELL TL, TRENDS BIOCHEM. SCI., (2010), vol. 36, page 141
    - YUAN B ET AL., CLIN. CANCER RES., (2006), vol. 12, page 405
    - ROBERTS BT ET AL., MOL. CELL BIOL., (1994), vol. 14, page 8282
    - ELOWE S, MOL. CELL. BIOL., (2011), vol. 31, page 3085
    - KAWASHIMA ET AL., SCIENCE, (2010), vol. 327, page 172
    - WATANABE Y, COLD SPRING HARB. SYMP. QUANT. BIOL., (2010), vol. 75, page 419
    - RICKE ET AL., J. CELL BIOL., (2012), vol. 199, pages 931 - 949
    - WEAVER BA; CLEVELAND DW, CANCER RES., (2007), vol. 67, page 10103
    - KING RW, BIOCHIM BIOPHYS ACTA, (2008), vol. 1786, page 4
    - KOPS GJ ET AL., NATURE REV. CANCER, (2005), vol. 5, page 773
    - SCHMIDT M; MEDEMA RH, CELL CYCLE, (2006), vol. 5, page 159
    - SCHMIDT M; BASTIANS H, DRUG RES. UPDATES, (2007), vol. 10, page 162
    - RIEDER CL; MAIATO H, DEV. CELL, (2004), vol. 7, page 637
    - PURE APPL CHEM, (1976), vol. 45, pages 11 - 30
    - S. M. BERGE ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - AIELLO ET AL., NEW ENGL. J. MED., (1994), vol. 331, page 1480
    - PEER ET AL., LAB. INVEST., (1995), vol. 72, page 638
    - LOPEZ ET AL., INVEST. OPTHTHALMOL. VIS. SCI., (1996), vol. 37, page 855
    - POWELL, M.F. ET AL., "Compendium of Excipients for Parenteral Formulations", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, (1998), vol. 52, no. 5, pages 238 - 311, XP009119027
    - STRICKLEY, R.G, "Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-1", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, (1999), vol. 53, no. 6, pages 324 - 349
    - NEMA, S. ET AL., "Excipients and Their Use in Injectable Products", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, (1997), vol. 51, no. 4, pages 166 - 171
    - Goodman and Gilman's The Pharmacological Basis of Therapeutics, MCGRAW-HILL, (1996), pages 1225 - 1287
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.